机译:诊断中的嗜中性粒细胞淋巴细胞比是结节性硬化症霍奇金淋巴瘤患者的独立预后因素:涉及990名患者的大型多中心研究的结果
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Hematology‐Oncology Unit Bnai Zion Medical Center and the Rappaport Faculty of;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Hematology UnitSant'andrea HospitalRome Italy;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Hematology UnitIRCSSReggio Emilia Italy;
Division of Hematology Fondazione IRCCS Cà GrandaUniversity of MilanMilan Italy;
Department of Internal MedicineUniversity of Pavia Fondazione IRCCS Policlinico S. MatteoPavia;
Hematology‐Oncology UnitEmek Medical CenterAfula Israel;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Department of HematologyHadassah University Hospital and Hebrew University Medical SchoolJerusalem;
Department of Diagnostic Clinical and Public Health MedicineUniversity of Modena and Reggio;
Hodgkin lymphoma; lymphocyte; neutrophil; neutrophil‐lymphocyte ratio; prognosis;
机译:诊断中的嗜中性粒细胞淋巴细胞比是结节性硬化症霍奇金淋巴瘤患者的独立预后因素:涉及990名患者的大型多中心研究的结果
机译:新诊断霍奇金淋巴瘤患者中嗜中性粒细胞比(NLR)和淋巴细胞对单核细胞淋巴瘤(LMR)对肝脏淋巴瘤患者的预后含义及其基于PET-2的策略
机译:衍生的中性粒细胞到淋巴细胞比是血管免疫细胞患者患者的独立预后因素。血管细胞淋巴瘤
机译:2017年Brsud Tabanan在Brsud Tabanan的急性心肌梗死患者入院和良好死亡率患者的淋巴细胞比率之间的联系
机译:非霍奇金淋巴瘤的老年患者的白细胞生长因子的临床结果和成本效益:基于大量人群的研究结果。
机译:诊断为结节性硬化的霍奇金淋巴瘤患者中的中性粒细胞-淋巴细胞比率是一个独立的预后因素:一项涉及990名患者的大型多中心研究的结果
机译:绝对单核细胞计数和淋巴细胞/单核细胞比率预测结节性硬化霍奇金淋巴瘤的预后:根据1450例患者的数据进行评估